(S (NP (NP (NNP Prostate) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NNP PCa)) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (DT the) (ADJP (RBS most) (JJ common)) (NN cancer)) (PP (IN in) (NP (NNS men))) (PP (IN in) (NP (DT the) (NNP United) (NNPS States))))) (. .))
(S (NP (NP (JJ Multiparametic) (JJ magnetic) (NN resonance) (NN imaging)) (PRN (-LRB- -LRB-) (NP (NN mp-MRI)) (-RRB- -RRB-))) (VP (VBZ has) (VP (VBN been) (VP (VBN explored) (PP (IN by) (NP (JJ many) (NNS researchers))) (PP (TO to) (NP (NP (VB targeted) (NN prostate) (NNS biopsies)) (CC and) (NP (NN radiation) (NN therapy))))))) (. .))
(S (ADVP (RB However)) (, ,) (S (NP (NP (NN assessment)) (PP (IN on) (NP (NN mp-MRI)))) (VP (MD can) (VP (VB be) (ADJP (JJ subjective))))) (, ,) (S (NP (NP (NN development)) (PP (IN of) (NP (NP (JJ computer-aided) (NN diagnosis) (NNS systems)) (SBAR (S (VP (TO to) (ADVP (RB automatically)) (VP (VB delineate) (NP (NP (DT the) (NN prostate) (NN gland)) (CC and) (NP (NP (DT the) (JJ intraprostratic) (NNS lesions)) (PRN (-LRB- -LRB-) (NP (NNP ILs)) (-RRB- -RRB-))))))))))) (VP (VBZ becomes) (ADJP (ADJP (JJ important)) (S (VP (TO to) (VP (VB facilitate) (PP (IN with) (NP (NP (NNS radiologists)) (PP (IN in) (NP (JJ clinical) (NN practice))))))))))) (. .))
(S (PP (IN In) (NP (DT this) (NN paper))) (, ,) (NP (PRP we)) (ADVP (RB first)) (VP (VBD study) (NP (NP (DT the) (NN implementation)) (PP (IN of) (NP (DT the) (NNP Mask-RCNN) (NN model))) (S (VP (TO to) (VP (NN segment) (NP (DT the) (NN prostate) (CC and) (NNP ILs))))))) (. .))
(S (NP (PRP We)) (VP (VBD trained) (CC and) (VBD evaluated) (NP (NNS models)) (PP (IN on) (NP (NP (CD 120) (NNS patients)) (PP (IN from) (NP (NP (CD two) (JJ different) (NNS cohorts)) (PP (IN of) (NP (NNS patients)))))))) (. .))
(S (NP (PRP We)) (ADVP (RB also)) (VP (VP (VBD used) (NP (NP (CD 2D) (JJ U-Net)) (CC and) (NP (CD 3D) (JJ U-Net))) (PP (IN as) (NP (NNS benchmarks))) (S (VP (TO to) (VP (NN segment) (NP (DT the) (NN prostate)))))) (CC and) (VP (VBN compared) (NP (NP (DT the) (NN model) (POS 's)) (NN performance)))) (. .))
(S (NP (NP (DT The) (JJ contour) (NN variability)) (PP (IN of) (NP (NP (NNP ILs)) (VP (VBG using) (NP (DT the) (NN algorithm)))))) (VP (VBD was) (ADVP (RB also)) (VP (VBN benchmarked) (PP (IN against) (NP (NP (DT the) (NN interobserver) (NN variability)) (PP (IN between) (NP (CD two) (JJ different) (NN radiation) (NNS oncologists))) (PP (IN on) (NP (CD 19) (NNS patients))))))) (. .))
(S (NP (PRP$ Our) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (DT the) (NNP Mask-RCNN) (NN model)) (VP (VP (VBZ is) (ADJP (JJ able) (S (VP (TO to) (VP (VB reach) (NP (NP (JJ state-of-art) (NN performance)) (PP (IN in) (NP (DT the) (NN prostate) (NN segmentation))))))))) (CC and) (VP (VBZ outperforms) (NP (JJ several) (JJ competitive) (NNS baselines)) (PP (IN in) (NP (NNP ILs) (NN segmentation)))))))) (. .))
